Sign Up For Updates
Sign up for updates
Join our mailing list to receive updates from the Drug Pricing Lab.
Thank you for signing up to receive news and information from the Drug Pricing Lab.
Return to Previous Page
U.S. Senate Committee on Finance: Dr. Bach Testifies at Committee's First Hearing of Session
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.
Drug Pricing Lab
January 30, 2019
Overview of Original Subscription Model and Features of LA and WA Proposals
Here we present our overview of the original subscription-based payment model proposed and the proposals put forth by Louisiana and Washington.
Drug Pricing Lab
January 29, 2019
The "Netflix Model" of Financing Hepatitis C Treatment
In a new piece in JAMA, Dr. Peter B. Bach, Sen. Bill Cassidy (R-LA) and Dr. Mark Trusheim outline an alternative payment model for HCV treatment - The "Netflix Model".
Journal of the American Medical Association
October 29, 2018
Indication Specific Pricing as a Pathway for Value Based Pricing
DrugPricingLab op-ed in StatNews discusses indication-specific pricing of Kymriah
August 31, 2017
High prices continue to limit access to Hepatitis C treatment
The Washington Post takes a deeper dive on the issues highlighted in the DPL's budget allocator tool
July 12, 2017
Louisiana revisits an old law to address drug pricing
Sarah Jane Tribble writes about a Louisiana proposal to lower the cost of Hepatitis C drugs. Tradeoffs to fund these treatments are enormous, as shown by the DPL's budget allocator tool.
May 3, 2017
The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C
Peter B. Bach and Mark R. Trusheim propose that the U.S. Government buy Gilead from its shareholders.
Evidence Driven Drug Pricing Project
January 17, 2017
No Results Found